Status of PCSK9 Monoclonal Antibodies in Australia.

Antibodies, Monoclonal / pharmacology Antibodies, Monoclonal, Humanized / pharmacology Anticholesteremic Agents / pharmacology Australia / epidemiology Cardiovascular Diseases / drug therapy Humans Incidence PCSK9 Inhibitors Proprotein Convertase 9 / immunology Treatment Outcome
Atherosclerosis Cardiovascular risk Lipids PCSK9 inhibitors

Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 18 02 2019
accepted: 27 04 2019
pubmed: 21 5 2019
medline: 29 1 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

Identifiants

DOI: 10.1016/j.hlc.2019.04.014 PMID: 31104887
pubmed: 31104887
pii: S1443-9506(19)30354-3
doi: 10.1016/j.hlc.2019.04.014
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Anticholesteremic Agents 0
PCSK9 Inhibitors 0
PCSK9 protein, human EC 3.4.21.-
Proprotein Convertase 9 EC 3.4.21.-
evolocumab LKC0U3A8NJ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1571-1579

Informations de copyright

Copyright © 2019 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Auteurs

Daniel J Scherer (DJ)

South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia; University of Adelaide, Adelaide, SA, Australia. Electronic address: daniel.scherer@sahmri.com.

Adam J Nelson (AJ)

South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia; University of Adelaide, Adelaide, SA, Australia.

Richard O'Brien (R)

Medicine, Austin Clinical School, University of Melbourne, Melbourne, Vic, Australia; Department of Endocrinology, Austin Health, Melbourne, Vic, Australia.

Karam M Kostner (KM)

Department of Cardiology, Mater Hospital, University of Queensland, Brisbane, Qld, Australia.

David L Hare (DL)

Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Vic, Australia; Department of Cardiology, Austin Health, Melbourne, Vic, Australia.

David M Colquhoun (DM)

School of Medicine, University of Queensland, Brisbane, Qld, Australia; Wesley Medical Centre, Wesley Hospital and Greenslopes Private Hospital, Brisbane, Qld, Australia.

Philip J Barter (PJ)

School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.

Philip Aylward (P)

Flinders University and Medical Centre, Adelaide, SA, Australia.

Stephen J Nicholls (SJ)

Department of Medicine, Monash University, Melbourne, Vic, Australia.

Gerald F Watts (GF)

School of Medicine, Faculty of Medicine and Health Sciences, University of Western Australia, Perth, WA, Australia; Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Maladies cardiovasculaires › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Inhibiteurs de PCSK9 › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Protéases à sérine › Serine endopeptidases › Proprotéine convertase 9 › Status of PCSK9 Monoclonal Antibodies in Australia.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Status of PCSK9 Monoclonal Antibodies in Australia.